Scilex Holding Co

Scilex Holding Co (ticker: SCLX) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of SCLX's SEC filings surfaces 7 active risk signals, including 4 late-filing signals, 2 auditor-change signals, and 1 delisting/deregistration signal. SCLX reported $30.25M in revenue and -$374.05M for the period ending 2025-12-31, with operating cash flow of $3.82M. Cash and equivalents stood at $4.96M (up 51.4% year-over-year). Total assets of $364.98M are exceeded by total liabilities of $576.73M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.

SCLX Cash Runway

Months-of-runway analysis for SCLX, derived directly from SEC XBRL: latest cash and operating cash flow, monthly burn rate, runway under current conditions. Historical trend + verbatim citation panel ships in Phase 2.

Coming in Phase 2

The dedicated per-ticker cash-runway page will surface a 6-8 quarter trend with the underlying us-gaap:CashAndCashEquivalentsAtCarryingValue + us-gaap:NetCashProvidedByUsedInOperatingActivities citations alongside each data point. In the meantime, see the ranked cross-company view:

All companies ranked by months-of-runway →

Related on SCLX

Share-count dilution →

Dilution is the natural counterpart to runway burn.

Going-concern history →

Auditor + management language across filings.